Journal of affective disorders · 2025
Supplementation of medium-chain triglycerides combined with docosahexaenoic acid improves cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Duan Huilian, Yang Tong, Li Chenyu, Xu Ning, Wang Moyan, Zhang Chunlai, Zhao Jiangang, Chen Yongjie, Yan Jing, Li Wen, Li Zhenshu, Ma Fei, Huang Guowei
Аннотация
BACKGROUND: Medium-chain triglycerides (MCT) and docosahexaenoic acid (DHA) could affect cognitive function, but their combination effects remain unclear. This randomized, double-blind, placebo-controlled trial aimed to evaluate effects of MCT and DHA supplementation, alone or in combination, on mild cognitive impairment (MCI) patients.
METHODS: A total of 280 MCI participants were randomly assigned to the placebo group, MCT group (14 g/d octanoic acid+10 g/d capric acid), DHA group (800 mg/d) and MCT + DHA (14 g/d octanoic acid, 10 g/d capric acid and 800 mg/d DHA) group, 70 individuals per group for 12 months. Cognitive function was assessed at baseline, 6 months and 12 months; blood indicators were analyzed at baseline and 12 months. This study is registered with Chinese Clinical Trial Registry (ChiCTR2200059641).
RESULTS: After 12 months intervention, compared with the placebo group, MCT group, DHA group and MCT + DHA group had statistically significant improvements in full scale IQ (β: 0.107, 95 % CI: 0.006, 0.208; β: 0.135, 95 % CI: 0.034, 0.235; β: 0.136, 95 % CI: 0.035, 0.237), serum total ketone body levels (β: 10.540, 95 % CI: 9.550, 11.531; β: 5.884, 95 % CI: 4.894, 6.875; β: 13.186, 95 % CI: 12.196, 14.176), and decreases in mtDNA deletions (β: -0.370, 95 % CI: -0.648, -0.092; β: -0.335, 95 % CI: -0.613, -0.056; β: -0.427, 95 % CI: -0.705, -0.148) and plasma Aβ42 levels (β: -3.318, 95 % CI: -5.571, -1.064; β: -3.218, 95 % CI: -5.472, -0.965; β: -2.906, 95 % CI: -5.160, -0.653).
CONCLUSIONS: Supplementation of MCT, DHA and their combination for 12 months can significantly improve cognitive function, mitochondria function and increase serum total ketone body levels in MCI individuals. Combined intervention was more beneficial than MCT or DHA alone.
METHODS: A total of 280 MCI participants were randomly assigned to the placebo group, MCT group (14 g/d octanoic acid+10 g/d capric acid), DHA group (800 mg/d) and MCT + DHA (14 g/d octanoic acid, 10 g/d capric acid and 800 mg/d DHA) group, 70 individuals per group for 12 months. Cognitive function was assessed at baseline, 6 months and 12 months; blood indicators were analyzed at baseline and 12 months. This study is registered with Chinese Clinical Trial Registry (ChiCTR2200059641).
RESULTS: After 12 months intervention, compared with the placebo group, MCT group, DHA group and MCT + DHA group had statistically significant improvements in full scale IQ (β: 0.107, 95 % CI: 0.006, 0.208; β: 0.135, 95 % CI: 0.034, 0.235; β: 0.136, 95 % CI: 0.035, 0.237), serum total ketone body levels (β: 10.540, 95 % CI: 9.550, 11.531; β: 5.884, 95 % CI: 4.894, 6.875; β: 13.186, 95 % CI: 12.196, 14.176), and decreases in mtDNA deletions (β: -0.370, 95 % CI: -0.648, -0.092; β: -0.335, 95 % CI: -0.613, -0.056; β: -0.427, 95 % CI: -0.705, -0.148) and plasma Aβ42 levels (β: -3.318, 95 % CI: -5.571, -1.064; β: -3.218, 95 % CI: -5.472, -0.965; β: -2.906, 95 % CI: -5.160, -0.653).
CONCLUSIONS: Supplementation of MCT, DHA and their combination for 12 months can significantly improve cognitive function, mitochondria function and increase serum total ketone body levels in MCI individuals. Combined intervention was more beneficial than MCT or DHA alone.